Paper · 27429508
Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma.
Jakubowska K and 8 others. Dis Markers, 2016. Cited by 60 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma. Papers, record 27429508. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27429508
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Carcinogenesis | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Matrix Metalloproteinase 2 | Major topic |
| Matrix Metalloproteinase 7 | Major topic |
| Matrix Metalloproteinase 9 | Major topic |
| Pancreatic Neoplasms | Major topic |
| Adenocarcinoma | |
| Case-Control Studies | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Immunoenzyme Techniques | |
| Male | |
| Middle Aged | |
| Neoplasm Grading | |
| Prognosis | |
| Stromal Cells |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24,203,626 | Immunohistochemical expression of MMP-7 protein and its serum level in colorectal cancer. | Folia Histochem Cytobiol | 2013 | https://conductscience.org/library/papers/24203626 | PubMed |
| 2 | 17,283,135 | Identification of pancreatic cancer stem cells. | Cancer Res | 2007 | https://conductscience.org/library/papers/17283135 | PubMed |
| 3 | 9,755,853 | Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. | FEBS Lett | 1998 | https://conductscience.org/library/papers/9755853 | PubMed |
| 4 | 25,621,068 | Expression levels of matrix metalloproteinase-9 in human gastric carcinoma. | Oncol Lett | 2015 | https://conductscience.org/library/papers/25621068 | PubMed |
| 5 | 18,630,474 | The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. | Anticancer Res | 2008 | https://conductscience.org/library/papers/18630474 | PubMed |
| 6 | 23,388,475 | Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma. | J Physiol Pharmacol | 2012 | https://conductscience.org/library/papers/23388475 | PubMed |
| 7 | 23,063,657 | Matrix metalloproteinases: changing roles in tumor progression and metastasis. | Am J Pathol | 2012 | https://conductscience.org/library/papers/23063657 | PubMed |
| 8 | 14,581,368 | Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14581368 | PubMed |
| 9 | 15,810,077 | Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. | World J Gastroenterol | 2005 | https://conductscience.org/library/papers/15810077 | PubMed |
| 10 | 11,181,677 | Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. | J Clin Oncol | 2001 | https://conductscience.org/library/papers/11181677 | PubMed |
1 to 10 of 28
See all 28 referencesCited by43
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,694,847 | Decoding Pancreatic Cancer Pain: From Tumor-Nerve Crosstalk to Targeted Analgesic Strategies. | Int J Med Sci | 2026 | https://conductscience.org/library/papers/42694847 | PubMed |
| 42,583,516 | Tumor Microenvironment-Responsive Nanoparticles for Pancreatic Cancer Imaging and Treatment. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42583516 | PubMed |
| 42,352,435 | MMPs' Impact on Carcinogenesis in Specific Organs and Systems. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42352435 | PubMed |
| 41,694,374 | CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2-CCL2, CCR5-CCL5, CCR4-CCL17/22, CCR6-CCL20, CCR7-CCL19/21. | Front Immunol | 2026 | https://conductscience.org/library/papers/41694374 | PubMed |
| 41,105,435 | Diagnostic valuation of MMP family members as biomarkers for pancreatic cancer: a systematic review and meta-analysis. | Biomark Med | 2025 | https://conductscience.org/library/papers/41105435 | PubMed |
| 40,443,651 | Integrated multi-omics profiling to establish an IGFBP-based prognostic score for pancreatic ductal adenocarcinoma: unraveling prognostic biomarkers, immune microenvironment crosstalk, and therapeutic implications. | Front Immunol | 2025 | https://conductscience.org/library/papers/40443651 | PubMed |
| 37,834,100 | Differential Effects of Pancreatic Cancer-Derived Extracellular Vesicles Driving a Suppressive Environment. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834100 | PubMed |
| 37,555,952 | Microbiota as the unifying factor behind the hallmarks of cancer. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/37555952 | PubMed |
| 36,964,133 | Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36964133 | PubMed |
| 36,013,494 | The Significance of FDG PET/CT-Derived Parameters in Determining Prognosis of Cases with Pancreatic Adenocarcinoma: A Prospective Study. | Medicina (Kaunas) | 2022 | https://conductscience.org/library/papers/36013494 | PubMed |
1 to 10 of 43
See all 43 cited byGenes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MMP2 | 4,313 | PubTator's text mining | https://conductscience.org/library/genes/4313 | NCBI Gene |
| MMP7 | 4,316 | PubTator's text mining | https://conductscience.org/library/genes/4316 | NCBI Gene |
| MMP9 | 4,318 | PubTator's text mining | https://conductscience.org/library/genes/4318 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27429508
GET https://conductscience.org/api/papers/v1/27429508/references?page=2